Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ATXS
Upturn stock ratingUpturn stock rating

Astria Therapeutics Inc (ATXS)

Upturn stock ratingUpturn stock rating
$6.41
Last Close (24-hour delay)
Profit since last BUY10.71%
upturn advisory
Consider higher Upturn Star rating
BUY since 20 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/08/2025: ATXS (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

9 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $28.67

1 Year Target Price $28.67

Analysts Price Target For last 52 week
$28.67 Target price
52w Low $3.56
Current$6.41
52w High $12.92

Analysis of Past Performance

Type Stock
Historic Profit 115.38%
Avg. Invested days 53
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/08/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 349.89M USD
Price to earnings Ratio -
1Y Target Price 28.67
Price to earnings Ratio -
1Y Target Price 28.67
Volume (30-day avg) 9
Beta 0.38
52 Weeks Range 3.56 - 12.92
Updated Date 07/8/2025
52 Weeks Range 3.56 - 12.92
Updated Date 07/8/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.88

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -22.56%
Return on Equity (TTM) -32.89%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 155215157
Price to Sales(TTM) -
Enterprise Value 155215157
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -7.57
Shares Outstanding 56434200
Shares Floating 30074360
Shares Outstanding 56434200
Shares Floating 30074360
Percent Insiders 0.49
Percent Institutions 106.43

ai summary icon Upturn AI SWOT

Astria Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Astria Therapeutics, Inc., formerly Integral Molecular, Inc., is a biopharmaceutical company. Founded in 2018, it focuses on developing therapies for rare and life-threatening allergic and immunological diseases.

business area logo Core Business Areas

  • Angioedema: Astria is focused on developing STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, for the treatment of hereditary angioedema (HAE).

leadership logo Leadership and Structure

The leadership team includes Jill C. Milne, Ph.D., Chief Executive Officer, and Andrea Matthews, Chief Financial Officer. The company operates with a standard organizational structure common to biopharmaceutical companies.

Top Products and Market Share

overview logo Key Offerings

  • STAR-0215: STAR-0215 is Astria's lead product candidate, a monoclonal antibody inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Market share data is not yet applicable as the product is still in clinical development. Competitors include Takeda (TAK) with Takhzyro, BioCryst Pharmaceuticals (BCRX) with Orladeyo, and CSL Behring with Haegarda and Berinert.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and research-intensive. The HAE market is growing with increasing awareness and diagnosis rates.

Positioning

Astria is positioned as an emerging player in the HAE market, aiming to provide a differentiated treatment option with STAR-0215.

Total Addressable Market (TAM)

The global hereditary angioedema (HAE) market is estimated to be in the billions. Astria is seeking to capture a share of this market with a novel treatment option for patients who may benefit from less frequent injections.

Upturn SWOT Analysis

Strengths

  • Novel Mechanism of Action (STAR-0215)
  • Experienced Management Team
  • Focus on a Specific Therapeutic Area (HAE)

Weaknesses

  • Single Product Candidate Dependence
  • Early Stage Clinical Development
  • High Cash Burn Rate

Opportunities

  • Positive Clinical Trial Results
  • Expansion to other Angioedema Types
  • Partnerships with Larger Pharmaceutical Companies

Threats

  • Competition from Established HAE Therapies
  • Clinical Trial Failures
  • Regulatory Hurdles
  • Patent Challenges

Competitors and Market Share

competitor logo Key Competitors

  • TAK
  • BCRX
  • CSL

Competitive Landscape

Astria's advantage lies in potentially providing a less frequent injection option. Disadvantages include being a smaller company competing against established players.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is reflected in the company's stock price, influenced by pipeline progress and financial performance.

Future Projections: Future growth is dependent on the successful development and commercialization of STAR-0215.

Recent Initiatives: Recent initiatives include advancing STAR-0215 through clinical trials, and presenting data at scientific conferences.

Summary

Astria Therapeutics is a clinical-stage biopharmaceutical company focused on HAE. Success hinges on clinical trial outcomes for STAR-0215. Key challenges include competing with established therapies and managing cash flow. The company needs to carefully manage its clinical trials and regulatory pathways, while also exploring ways to expand its product pipeline and revenue streams to ensure long-term success. Its novel approach to reducing injection frequency could be a significant advantage, if clinical data supports it.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings (10-K, 10-Q)
  • Analyst Reports
  • Industry Publications

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated. Clinical trial results are subject to change. Investment decisions should be based on individual due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Astria Therapeutics Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2015-06-25
Co-Founder, CEO, President & Director Ms. Jill C. Milne Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 78
Full time employees 78

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.